Certolizumab pegol (CZP) is an Fc-free, PEGylated anti-tumour necrosis factor biologic.Report three-year safety from three phase 3 trials of CZP in adults with plaque psoriasis (PSO).Data were pooled from CIMPASI-1 (NCT02326298), CIMPASI-2 (NCT02326272), CIMPACT (NCT02346240). Included patients: had moderate to severe PSO ≥6 months; were randomised to CZP 200 mg every two weeks (Q2W) (400 mg at Weeks 0, 2, 4) or CZP 400 mg Q2W; received ≥1 dose CZP with up to 144 weeks' exposure. Treatment-emergent adverse events (TEAEs) were classified using MedDRAv18.1. Reported incidence rates (IRs) are incidence of new cases/100 patient-years (PY).Over 144 weeks, 995 patients received ≥1 dose CZP (exposure: 2,231.3 PY); 731 and 728 received ≥1 dose CZP 200 mg Q2W (1,211.4 PY) and 400 mg Q2W (1,019.9 PY), respectively. IR (95% confidence interval [CI]) of TEAEs was 144.9 (135.3-155.0) for all patients; 134.1 (123.2-145.7) and 158.3 (145.5-171.9) for CZP 200 mg and 400 mg Q2W, respectively. IR of serious TEAEs for all patients was 7.5 (6.4-8.8); 6.7 (5.2-8.3) and 8.7 (6.9-10.8) for CZP 200 mg and 400 mg Q2W, respectively. 3.2% patients reported serious infections (2.2% within each of the CZP 200 and 400 mg Q2W groups). Overall, there was 1 case of active tuberculosis, 16 malignancies in 14 patients and 7 deaths (2 considered treatment-related). Cumulative IR of TEAEs did not increase over time.No new safety signals were identified compared to previously reported data. Risk did not increase with longer or higher CZP exposure.

Click here to read the full article @ The British journal of dermatology